Research
Hormonal
Obesity is associated with gut microbiota dysbiosis characterized by reduced diversity, altered taxonomic abundance, and impaired gut-brain axis communication, leading to dysregulated appetite and energy homeostasis.
Obesity is linked to changes in gut bacteria that disrupt signals for hunger and fullness. These changes include lower bacterial diversity and reduced production of satiety hormones. Understanding this link highlights why dietary changes can help reset these signals.
GoodSupportsHIGH confidence
In fact, individuals with obesity display dysbiosis, which is characterised by a less diverse gut microbiota, a higher production of pro-inflammatory mediators, and by an enhanced intestinal permeability... individuals with obesity exhibit impairments in both the homeostatic and hedonic pathways regulating food-related behaviour, which may contribute to dysfunctional eating patterns and, ultimately, overfeeding
Why this rating
Supported by multiple observational and preclinical studies cited in the review.
Source
The Gut–Brain Axis in Obesity: Mechanisms, Development, and Therapeutic Perspectives
Laura Arellano-García et al. · Current Nutrition Reports · 2026
DOI 10.1007/s13668-026-00732-w
narrative_reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Caloric restriction interventions restore gut-brain axis communication in obesity by enriching beneficial bacteria (e.g., Akkermansia muciniphila), reducing LPS-mediated endotoxemia, and modulating SCFA production to enhance satiety signaling.Good
- GLP-1 receptor agonists (Liraglutide and Semaglutide) promote weight loss and modulate gut microbiota towards a lean-related profile, although clinical data on their specific impact on gut microbiota composition is currently limited.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →